Other PSA‐based tests such as %‐free PSA,36 [−2]pro‐PSA (p2PSA),37 and Prostate Health Index (PHI)38 with documented sensitivity/specificity trade‐off36, 39, 40 are currently not recommended or approved for routine prostate cancer screening. The gene discussed is KLK3; the disease is prostate carcinoma.